S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:ALPN

Alpine Immune Sciences (ALPN) Stock Price, News & Analysis

$39.64
+0.99 (+2.56%)
(As of 03/28/2024 ET)
Today's Range
$37.18
$41.04
50-Day Range
$18.56
$41.60
52-Week Range
$6.71
$42.88
Volume
1.46 million shs
Average Volume
1.13 million shs
Market Capitalization
$2.60 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.86

Alpine Immune Sciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
2.0% Downside
$38.86 Price Target
Short Interest
Bearish
8.56% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.83mentions of Alpine Immune Sciences in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$5,192 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.76) to ($1.92) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.51 out of 5 stars

Medical Sector

724th out of 938 stocks

Pharmaceutical Preparations Industry

329th out of 426 stocks

ALPN stock logo

About Alpine Immune Sciences Stock (NASDAQ:ALPN)

Alpine Immune Sciences, Inc. operates as a clinical-stage immunotherapy company. It focuses on creating various immunotherapies through protein engineering technologies for autoimmune and inflammatory diseases. The company has strategic collaborations with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development. Its pipeline includes Povetacicept, a dual B cell cytokine antagonist for multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways for treatment of severe inflammatory diseases. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

ALPN Stock Price History

ALPN Stock News Headlines

Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
Evaluating Alpine Immune Sciences: Insights From 6 Financial Analysts
Q4 2023 Alpine Immune Sciences Inc Earnings Call
See More Headlines
Receive ALPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alpine Immune Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALPN
Employees
126
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$38.86
High Stock Price Target
$50.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+0.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-32,180,000.00
Pretax Margin
-54.49%

Debt

Sales & Book Value

Annual Sales
$58.88 million
Book Value
$5.64 per share

Miscellaneous

Free Float
37,820,000
Market Cap
$2.53 billion
Optionable
Optionable
Beta
1.13
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Dr. Mitchell H. Gold M.D. (Age 56)
    Executive Chairman & CEO
    Comp: $778.2k
  • Dr. Stanford Peng M.D. (Age 53)
    Ph.D., President and Head of Research & Development
    Comp: $751.2k
  • Mr. Paul Rickey (Age 45)
    Senior VP, CFO, Treasurer & Secretary
    Comp: $577.1k
  • Ms. M. Christina Yi (Age 47)
    Chief Technology Officer
  • Temre Johnson
    Head of IR & Corporate Communications
  • Dr. Remy Durand Ph.D. (Age 39)
    Chief Business Officer
  • Dr. Wolfgang Dummer M.D. (Age 58)
    Ph.D., Chief Medical Officer

ALPN Stock Analysis - Frequently Asked Questions

Should I buy or sell Alpine Immune Sciences stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALPN shares.
View ALPN analyst ratings
or view top-rated stocks.

What is Alpine Immune Sciences' stock price target for 2024?

7 equities research analysts have issued twelve-month target prices for Alpine Immune Sciences' shares. Their ALPN share price targets range from $18.00 to $50.00. On average, they anticipate the company's share price to reach $38.86 in the next twelve months. This suggests that the stock has a possible downside of 2.0%.
View analysts price targets for ALPN
or view top-rated stocks among Wall Street analysts.

How have ALPN shares performed in 2024?

Alpine Immune Sciences' stock was trading at $19.06 on January 1st, 2024. Since then, ALPN shares have increased by 108.0% and is now trading at $39.64.
View the best growth stocks for 2024 here
.

Are investors shorting Alpine Immune Sciences?

Alpine Immune Sciences saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 5,610,000 shares, an increase of 26.6% from the February 29th total of 4,430,000 shares. Based on an average daily volume of 1,100,000 shares, the days-to-cover ratio is presently 5.1 days.
View Alpine Immune Sciences' Short Interest
.

When is Alpine Immune Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ALPN earnings forecast
.

How were Alpine Immune Sciences' earnings last quarter?

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) issued its quarterly earnings data on Tuesday, November, 9th. The biotechnology company reported ($0.55) EPS for the quarter, missing the consensus estimate of $0.01 by $0.56. The biotechnology company had revenue of $8.52 million for the quarter, compared to analysts' expectations of $22.30 million. Alpine Immune Sciences had a negative trailing twelve-month return on equity of 15.54% and a negative net margin of 54.66%.

What ETF holds Alpine Immune Sciences' stock?

AdvisorShares Dorsey Wright Micro-Cap ETF holds 2,351 shares of ALPN stock, representing 0.65% of its portfolio.

What other stocks do shareholders of Alpine Immune Sciences own?
Who are Alpine Immune Sciences' major shareholders?

Alpine Immune Sciences' stock is owned by many different retail and institutional investors. Top institutional investors include Decheng Capital LLC (12.19%), Great Point Partners LLC (6.37%), Frazier Life Sciences Management L.P. (5.39%), Vanguard Group Inc. (3.85%), Vanguard Group Inc. (3.85%) and Price T Rowe Associates Inc. MD (2.90%). Insiders that own company stock include Decheng Capital China Life Sci, James Paul Rickey, Life Sciences Viii L Frazier, Mitchell Gold, Orbimed Advisors Llc, Peter A Thompson and Robert E Conway.
View institutional ownership trends
.

How do I buy shares of Alpine Immune Sciences?

Shares of ALPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALPN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners